TEVA · NYSE · STOCK
Teva Pharmaceutical Industries (TEVA) Stock Analysis
$41.07
52W $18.83 – $42.02
46/100
$47.87B
62.2
0.82
Is TEVA Bullish or Bearish?
Mixed.
Innellis AI committee rates Teva Pharmaceutical Industries Limited (TEVA) Watch with a composite score of 46/100
, based on 6 analysts with 50% agreement.
Last updated October 10, 2026.
What Would Change This View
- Upgrade to Buy
- Requires a committee score of 60.0 — +13.93 from today. Applies on the first day at or above the line; upgrades are never dampened.
- Downgrade to Reduce
- Requires the score to fall below 40.0 — -6.07 from today. The band boundary is 45.0, but a one-step downgrade must clear a further margin first. A score oscillating around the line should not change the rating every night.
Executive Summary
The committee is genuinely divided. Macro Analyst sees a compelling case. Value Analyst remains cautious — p/e of 63.3 is expensive by classic value standards. This disagreement is itself the signal — the setup is not clean in either direction.
Bull & Bear Case
Bull Case
- Price structure making higher highs and higher lows — Technical
- Trend and market structure agree -- coherent bullish picture — Technical
- Weekly trend (uptrend) confirms the daily trend -- multi-timeframe agreement — Technical
Bear Case
- P/E of 63.3 is expensive by classic value standards — Value
- Price-to-book of 4.8x prices in significant intangible value — Value
- Debt-to-equity of 2.12 adds balance-sheet risk to the value case — Value
- Growth rate is decelerating quarter over quarter -- the trend line matters more than the level — Growth
- RSI at 72 is in overbought territory — Technical
- MACD histogram negative -- bearish momentum — Technical
Both cases are generated from quantitative data signals, not qualitative or
forward-looking judgement. They summarise what the numbers say today.
Price History (6M)
AI Investment Committee
Committee Consensus
As of October 10, 2026
Overall Committee Score
46/100
Agreement
50%
Analysts
6
Conviction
Contested
Sector Rank
Top 98%
of 192 Healthcare peers
Value Analyst
bearish
28
/ 100 · Moderate confidence
Multiples don't clear a genuine value bar here, or cheapness looks justified by weak fundamentals
− P/E of 63.3 is expensive by classic value standards
Growth Analyst
bearish
38
/ 100 · Moderate confidence
Growth story is weak, decelerating, or inconsistent
− Growth rate is decelerating quarter over quarter -- the trend line matters more than the level
Technical Analyst
neutral
54
/ 100 · High confidence
Mixed or range-bound price action
+ Price structure making higher highs and higher lows
− RSI at 72 is in overbought territory
Risk Analyst
bearish
30
/ 100 · Low confidence
Elevated risk from leverage, volatility, event exposure, or portfolio concentration -- size accordingly
− High leverage (debt-to-equity 2.12) amplifies downside in a stress scenario
Macro Analyst
bullish
65
/ 100 · Low confidence
Macro backdrop is supportive of risk assets generally, and this name's beta works in its favor
News Analyst
bullish
62
/ 100 · Low confidence
News flow and recent filings/analyst actions are net positive
Portfolio Manager
bearish
30
/ 100 · Moderate confidence
The existing book itself argues for caution here, independent of how good this specific stock looks
− Sector concentration is already high (HHI 2796.97)
Investment Thesis Evolution
Committee score moved marginally from 48.4 to 46.1.
- New bearish signals: 5 appeared.
- Bullish support removed: 1 signal(s) disappeared.
- Bearish pressure eased: 2 signal(s) disappeared.
- Analyst(s) changed stance: Technical Analyst.
Analyst-level changes:
- News Analyst: score 68->62 (-6).
- Technical Analyst: stance bullish->neutral; score 61->54 (-8); +3 bearish signal(s).
- Value Analyst: +2 bearish signal(s).
Comparing 2026-10-09 to 2026-10-10 (1 day apart).
Technical Analysis
RSI (14)
72.0
Overbought
MACD Histogram
-0.035
Bearish Momentum
Trend Direction
Uptrend
Weekly: Uptrend
Market Structure
Hh Hl
Bollinger %B
1.20
Above Upper Band
Price vs Moving Averages
EMA 9
$39.65
Above
EMA 21
$39.07
Above
EMA 50
$37.66
Above
EMA 200
$33.10
Above
Fundamental Analysis
Valuation
44
Growth
19
Profitability
56
Financial Health
12
Cash Flow
70
Valuation
P/E Ratio
62.2×
P/B Ratio
5.89×
PEG Ratio
0.11
Dividend Yield
0.00%
52W High
$42.02
52W Low
$18.83
Quality & Growth
ROE
1782.6%
ROA
346.0%
Gross Margin
5245.8%
Operating Margin
1492.5%
Revenue Growth YoY
—
Debt / Equity
2.16
AI Fundamental Assessment
P/E ratio of 62.2 (rich relative to a 15-40x range); Price-to-book of 5.9x; PEG ratio of 0.1 (under 1.0 suggests growth is undervalued relative to price); Return on equity of 17.8%; Return on assets of 3.5%; Net margin of 4.1%; Gross margin of 52.5%; Current ratio of 0.88 (tight short-term liquidity); Debt-to-equity of 2.16; Free cash flow per share is positive (2.04); Most recent quarter missed estimates by 92.1%; EPS growth decelerating (-44.8% -> -96.2% QoQ); Analyst estimates falling over recent quarters
Get the Full TEVA Analysis
Interactive charts · Live committee votes · Trade plan · Paper trading · AI Q&A
Open in Terminal →